Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market (2025-2031) | Trends, Growth, Segmentation, Outlook, Analysis, Forecast, Industry, Size & Revenue, Share, Companies, Competitive Landscape, Value

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 Israel Country Macro Economic Indicators

3.2 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, 2021 & 2031F

3.3 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market - Industry Life Cycle

3.4 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market - Porter's Five Forces

3.5 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume Share, By GLP-1 Receptor Agonists, 2021 & 2031F

3.6 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume Share, By Insulin Drugs, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of diabetes in Israel

4.2.2 Growing awareness about the benefits of insulin drugs and GLP-1 receptor agonists

4.2.3 Technological advancements in diabetes treatment

4.3 Market Restraints

4.3.1 Stringent regulatory requirements for drug approval

4.3.2 High cost associated with insulin drugs and GLP-1 receptor agonists

4.3.3 Limited access to healthcare services in certain regions of Israel

6.1 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, By GLP-1 Receptor Agonists

6.1.1 Overview and Analysis

6.1.2 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By GLP-1 Receptor Agonists, 2021- 2031F

6.1.3 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Exenatide, 2021- 2031F

6.1.4 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Liraglutide (Victoza), 2021- 2031F

6.1.5 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Lixisenatide (Lyxumia), 2021- 2031F

6.1.6 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Dulaglutide (Trulicity), 2021- 2031F

6.1.7 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Semaglutide (Ozempic), 2021- 2031F

6.2 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, By Insulin Drugs

6.2.1 Overview and Analysis

6.2.2 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Basal or Long-acting Insulins, 2021- 2031F

6.2.3 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Bolus or Fast-acting Insulins, 2021- 2031F

6.2.4 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Traditional Human Insulins, 2021- 2031F

6.2.5 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Combination Insulins, 2021- 2031F

6.2.6 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Biosimilar Insulins, 2021- 2031F

7.1 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Export to Major Countries

7.2 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Imports from Major Countries

8.1 Number of new diabetes cases diagnosed annually in Israel

8.2 Adoption rate of insulin drugs and GLP-1 receptor agonists among healthcare providers

8.3 Patient adherence and compliance rates to prescribed diabetes medications

8.4 Number of research and development activities focused on diabetes treatment in Israel

9.1 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Opportunity Assessment, By GLP-1 Receptor Agonists, 2021 & 2031F

9.2 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Opportunity Assessment, By Insulin Drugs, 2021 & 2031F

10.1 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenue Share, By Companies, 2024

10.2 Israel Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Competitive Benchmarking, By Operating and Technical Parameters